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Autophagy is a membrane-trafficking process that
directs degradation of cytoplasmic material in lyso-
somes. The process promotes cellular fidelity, and
while the core machinery of autophagy is known,
the mechanisms that promote and sustain auto-
phagy are less well defined. Here we report that the
epigenetic reader BRD4 and the methyltransferase
G9a repress a TFEB/TFE3/MITF-independent tran-
scriptional program that promotes autophagy and
lysosome biogenesis. We show that BRD4 knock-
down induces autophagy in vitro and in vivo in
response to some, but not all, situations. In the
case of starvation, a signaling cascade involving
AMPK and histone deacetylase SIRT1 displaces
chromatin-bound BRD4, instigating autophagy
gene activation and cell survival. Importantly, this
program is directed independently and also recipro-
cally to the growth-promoting properties of BRD4
and is potently repressed by BRD4-NUT, a driver of
NUT midline carcinoma. These findings therefore
identify a distinct and selective mechanism of auto-
phagy regulation.
INTRODUCTION
(Macro) autophagy is a catabolic process that delivers intracel-
lular constituents and organelles to lysosomes for degradation
(Mizushima et al., 2008). This process operates at basal levels
in virtually all cells and contributes to the preservation of cellular
fidelity. Autophagy can also be activated by various stresses andMolecular Cell 66, 517–532
This is an open access article undsignaling cues to promote the degradation of specific species to
bring about selective desired effects within cells (Khaminets
et al., 2016; Rabinowitz and White, 2010). The importance of
the process is exemplified by the fact that its dysregulation is
implicated in various diseases, including neuronal degeneration,
immune diseases, and cancer (Mizushima et al., 2008).
Autophagy is initiated by the formation of double-membraned
structures called phagophores that originate from endoplasmic
reticulum (ER)-derived omegasomes as well as other sources
(Ktistakis and Tooze, 2016). As phagophores grow, they form
sphere-like structures called autophagosomes that sequester
and entrap cytoplasmic components. Autophagosomes can
then fuse with other organelles, such as endosomes, but ulti-
mately, fusion occurs with lysosomes forming autolysosomes
within which cargo digestion occurs (Ktistakis and Tooze,
2016). Intensive studies have identified the genes involved in
the various steps of autophagy, which has led to an established
basicmachinery for this complicated vesicular trafficking system
(Ktistakis and Tooze, 2016; Lamb et al., 2013).
Numerous signaling pathways that regulate autophagy in
response to specific stimuli have been identified (Lamb et al.,
2013). Recent accumulating evidence has also highlighted the
importance of transcriptional regulation of autophagy to sustain
prolonged autophagy and/or maintain basal autophagy (Baek
and Kim, 2017; F€ullgrabe et al., 2014, 2016). The precise control
of suppression and de-repression of autophagy is essential as
both excess and insufficient autophagy activation has been
shown to be deleterious to cells (Mizushima et al., 2008). How-
ever, the detailed regulatory mechanisms controlling autophagy
in both general and specific contexts remain largely unknown.
Successful completion of autophagy also requires functional
lysosomes, acidic organelles that contain various acid hydro-
lases for the degradation of macromolecules (Shen and Mizush-
ima, 2014). Lysosomal dysfunction impairs the degradation
of autophagic cargo, as well as molecules delivered by the, May 18, 2017 ª 2017 The Authors. Published by Elsevier Inc. 517
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endocytic pathway, macropinocytosis, and chaperone-medi-
ated autophagy, which in turn causes diseases, including
neuronal degeneration and lysosomal storage disorders (Shen
and Mizushima, 2014). In the course of an increased autophagic
response, lysosome biogenesis and function must also be
enhanced to support increased cargo degradation, yet the
mechanism underlying this effect is poorly understood. Recent
reports have shown that the coordinated activation of the auto-
phagy-lysosome pathway is governed by several transcription
factors, including transcription factor EB (TFEB) (Settembre
et al., 2011). Following certain autophagic stimuli, TFEB translo-
cates to the nucleus and activates a subset of autophagy and
lysosome genes. This enhances autophagosome formation,
their fusion with lysosomes, and lysosome biogenesis and func-
tion (Settembre et al., 2011).
Bromodomain-containing protein 4 (BRD4) is a member of the
bromodomain and extraterminal (BET) family proteins character-
ized by two N-terminal bromodomains and an extraterminal (ET)
domain (Shi and Vakoc, 2014). BRD4 binds to acetylated his-
tones and transcription factors through bromodomains and re-
cruits transcriptional regulators such as positive transcription
elongation factor b (P-TEFb) and Mediator complex (Shi and
Vakoc, 2014). BRD4 is involved in the activation of genes
involved in cell growth and cell cycle progression (Wang and Fil-
ippakopoulos, 2015). As a result, intensive studies have been
focused on the role of BRD4 in cancer, and BET inhibitors
have been proven to have efficacy against various types of tu-
mors (Wang and Filippakopoulos, 2015). Intriguingly, recent
accumulating evidence has shown that BRD4 also plays a role
in different biological processes, including memory formation,
mitochondrial oxidative phosphorylation, and DNA damage
response (Barrow et al., 2016; Floyd et al., 2013; Korb et al.,
2015). However, our understanding of the biological role of
BRD4 requires further investigation.
Here, by using RNAi screening and transcriptome analysis, we
have identified BRD4 as a transcriptional repressor of autophagy
and lysosomal function. We show that BRD4 suppresses the
expression of a subset of autophagy and lysosome genes by
binding to the promoter regions under normal growth conditions
and that this repression is alleviated in response to certain auto-
phagic stimuli. Inhibition of BRD4 enhances autophagic flux and
lysosomal function, which consequently promotes the degrada-
tion of pathogenic protein aggregates and confers the resistance
to starvation-induced cell death. These observations thereforeFigure 1. BRD4 Silencing Enhances Autophagic Flux
(A) Drosophila S2R+ cells expressing GFP-LC3 were transfected with double-str
(B and C) KP-4 cells transfected with control or BRD4 siRNA for 72 hr were subje
puncta normalized to cell number is shown. CON: n = 94 cells, BRD4 1: n = 97 c
(D) Immunohistochemistry of small intestinal sections from transgenic mice harbo
(upper) and BRD4 (lower). Cytoplasmic signal in BRD4 panels is due to non-spe
(E) KP-4 cells transfected with BRD4 siRNA were treated with 10 mM CQ for 4 hr
(F) KP-4 cells transfected with BRD4 siRNAwere stained for WIPI2. The number of
n = 107 cells, BRD4 2: n = 109 cells. Scale bars, 20 mm.
(G) KP-4 cells stably expressing RFP-GFP-LC3 were transfected with BRD4 siRN
(H) KP-4 cells were treated with 500 nM JQ1 for 9 hr in the presence or absence
(I) KP-4 cells overexpressing BRD4 were treated with 10 mM CQ for 4 hr.
(J) TY-82 cells transfected with NUT siRNA for 5 days were treated with 10 mM C
All data are shown as mean ± SD. *p < 0.01. See also Figure S1.provide important insights into a regulatory mechanism control-
ling autophagy and lysosome function.
RESULTS
BRD4 Is a Repressor of Autophagy
To understand the regulatory mechanisms of autophagy, we
conducted an RNAi screen using Drosophila S2R+ cells stably
expressing GFP-LC3 (Wilkinson et al., 2011). Double-stranded
RNA targeting female sterile (1) homeotic (Fs(1)h) was one of
the hits that increased GFP-LC3 puncta (Figure 1A). Fs(1)h is a
BET protein that functions as a scaffold protein bridging acety-
lated histones and transcriptional regulators (Kellner et al.,
2013). The mammalian BET family consists of four members:
ubiquitously expressed BRD2, BRD3, and BRD4 and testis-spe-
cific BRDT (Shi and Vakoc, 2014). To validate the screening re-
sults, we knocked down the genes encoding BRD2, BRD3, or
BRD4 in human pancreatic ductal adenocarcinoma KP-4 cells
and determined their effects on autophagy by monitoring the
levels of the lipidated form of LC3 (LC3II)—a marker of autopha-
gosome formation/accumulation (Klionsky et al., 2016). This re-
vealed that knockdown of BRD4, but not BRD2 and BRD3, led
to an increase in LC3II levels (Figure 1B; Figures S1A and
S1B). The generality of this finding was confirmed using a panel
of different cell lines (Figure S1C). Consistent with LC3II accumu-
lation, the number of LC3 puncta, an indicator of autophago-
some formation (Klionsky et al., 2016), was also increased in
BRD4 knockdown cells (Figure 1C). Furthermore, analysis of in-
testinal sections from mice expressing an inducible BRD4
shRNA revealed that LC3 lipidation and puncta also increased
in vivo upon knockdown of BRD4 (Figure 1D; Figure S1D).
There are three BRD4 isoforms reported—isoform A (referred
to as long isoform) that possesses a carboxy-terminal domain
(CTD) containing the binding site for P-TEFb, isoformB that lacks
the CTD and has a unique 77 amino acid extension at its C termi-
nus, and isoform C (referred to as short isoform) that is the
shortest isoform lacking the CTD (Figure S1E). Isoform-specific
function of BRD4 has been described (Floyd et al., 2013). Knock-
down of either the short or the long isoform of BRD4 had no
effect on LC3II, while simultaneous depletion of both isoforms
promoted LC3 lipidation (Figures S1F and S1G), indicating that
BRD4 short and long isoforms are functionally redundant in the
regulation of autophagy. Of note, we could not detect BRD4 iso-
form B in KP-4 cells.anded RNA (dsRNA) targeting control luciferase (Luc) or Fs(1)h.
cted to western blot analysis (B) and stained for LC3B (C). The number of LC3
ells, BRD4 2: n = 74 cells. Scale bars, 50 mm.
ring inducible renilla luciferase or BRD4 shRNA. Sections were stained for LC3
cific staining. Scale bars, 50 mm.
.
WIPI2 puncta normalized to cell number is shown. CON: n = 119 cells, BRD4 1:
A. Scale bars, 50 mm.
of CQ (10 mM, 4 hr).
Q for 8 hr. BRD4-NUT was detected using NUT antibody.
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As LC3II accumulation is attributed to either increased auto-
phagy induction or impaired autophagosome turnover, the effect
of BRD4 knockdown on autophagic flux was examined in the
presence of chloroquine (CQ), an inhibitor of lysosomal degrada-
tion (Klionsky et al., 2016). As shown in Figures 1E, S1H, and S1I,
BRD4 silencing increased LC3II levels in the presence of CQ,
suggesting that BRD4 knockdown enhances autophagic flux.
To further examine the stage at which BRD4 affects auto-
phagy, we first examined the recruitment of WD repeat domain
phosphoinositide interacting 2 (WIPI2) to phosphatidylinositol
3-phosphate (PI3P)-enriched membrane—an event that pre-
cedes LC3 lipidation and which is used as a marker of early
stages of autophagy induction (Klionsky et al., 2016). This re-
vealed that an increased number of WIPI2 puncta were also
observed in BRD4-silenced cells (Figure 1F). In addition, we per-
formed a detailed examination of LC3 localization by using RFP-
GFP-tandem-tagged LC3 (Kimura et al., 2007). Due to the acid
lability of GFP in (auto)lysosomes, this revealed an increase in
GFP/RFP+ autolysosomes and also, to lesser extent, GFP+/
RFP+ phagophores/autophagosomes in BRD4 knockdown cells
(Figure 1G), suggesting that BRD4 knockdown promotes the for-
mation of autophagosomes and subsequent fusion with lyso-
somes. Autophagy receptors, such as p62/SQSTM1, are
degraded together with cargos and are used as readouts of au-
tophagic degradation (Klionsky et al., 2016). Consistently, BRD4
silencing led to a reduction in exogenously expressed GFP-p62
levels, and this p62 degradationwas blocked byCQ (Figure S1J).
BET inhibitors displace BRD proteins from promoter and
enhancer regions, thereby interfering with BRD-mediated tran-
scriptional regulation (Shi and Vakoc, 2014). Similar to the results
we obtained in BRD4 knockdown cells, BET inhibitor JQ1 (Fili-
ppakopoulos et al., 2010) increased LC3II levels (Figure 1H; Fig-
ures S1K and S1L). As this did not occur in the absence of BRD4
(Figure S1M), we conclude that autophagy activation by JQ1 is
attributed to BRD4 inhibition. In addition, increased LC3 lipida-
tion and puncta formation were observed in mice treated with
JQ1 (Figures S1N and S1O). Similarly, we found that the BET
degrader ARV-825 (Lu et al., 2015) also activates autophagy
(Figure S1P). Conversely, overexpression of BRD4 suppressed
autophagic flux (Figure 1I; Figure S1Q). Collectively, these re-
sults identify BRD4 as a conserved negative regulator of
autophagy.
Chromosomal translocation of BRD4 to the locus encoding
nuclear protein in testis (NUT) causes NUT midline carcinoma
(NMC), a rare aggressive subtype of squamous cell carcinoma
(French, 2010). The fusion gene product BRD4-NUT possesses
two N-terminal bromodomains, an ET domain, and almost the
full length of NUT at its C terminus (Figure S1E) (French, 2010).
As a result, we were interested to know whether BRD4-NUT
also functions as a suppressor of autophagy. By taking advan-
tage of the testis-specific expression of NUT, we used small
interfering RNA (siRNA) against NUT to knockdown BRD4-NUT
(Schwartz et al., 2011). Inhibition of BRD4-NUT by NUT siRNAs
or JQ1 caused accumulation of LC3II in the presence of CQ in
the TY-82 NMC cell line (Figure 1J; Figures S1R and S1S), and
the effect of JQ1 treatment on LC3 lipidation was comparable
to that of BRD4-NUT knockdown (Figure S1T). BRD4-NUT
knockdown also increased the formation of GFP/RFP+ LC3520 Molecular Cell 66, 517–532, May 18, 2017puncta, indicating an accumulation of autolysosomes (Fig-
ure S1U). Interestingly, knockdown of BRD4 expressed from
the unaffected allele had little effect on autophagy compared
to BRD4-NUT knockdown (Figure S1V), suggesting that BRD4-
NUT fusion protein is a dominant repressor of autophagy
in NMC.
BRD4 Is a Negative Regulator of Autophagy Gene
Expression
As BRD4 is a transcriptional regulator, we hypothesized that
BRD4 regulates autophagy at the transcriptional level. RNA
sequencing (RNA-seq) analysis followed by reverse transcrip-
tase quantitative PCR (RT-qPCR) validation revealed that a sig-
nificant number of autophagy genes were upregulated upon
knockdown of BRD4 (Figures 2A and 2B; Figures S2A–S2D).
These include genes that encode proteins involved in autopha-
gosome formation (BECN1, VMP1, PIK3C3, WIPI1, ATG2A,
ATG9B, and MAP1LC3B) (Lamb et al., 2013), autophagy cargo
recruitment (SQSTM1 and OPTN), autophagosome-lysosome
fusion (PLEKHM1, TECPR1, and HOPS complex components)
(McEwan et al., 2015a), and maintenance of functional ER exit
sites and autophagosome formation (MAP1LC3C, TECPR2,
and SEC24D) (Stadel et al., 2015). BET inhibitors also led to up-
regulation of autophagy genes (Figure 2C). Of note, de-repres-
sion of autophagy genes was observed almost immediately after
JQ1 addition (Figure 2D), implying that these autophagy genes
are directly regulated by BRD4. In addition, we found that over-
expression of BRD4 repressed autophagy gene expression (Fig-
ure 2E; Figure S2E). As it is well established that BRD4 can form a
complex with P-TEFb and facilitate productive elongation at pro-
moter-proximal regions (Shi and Vakoc, 2014), we considered
that the effect on autophagy may also be through this mecha-
nism. We found, however, that knockdown of cyclin-dependent
kinase 9 (CDK9), a subunit of P-TEFb, had no effect on LC3II
levels (Figures S2F and S2G). This rules out the involvement of
P-TEFb in this response and indicates that BRD4 modulates
autophagy through a distinct pathway.
BRD4 Regulates Lysosome Gene Expression and
Lysosomal Function
As significant changes in lysosome gene expression occur upon
BRD4 knockdown (Figure 2A), this prompted us to examine
whether these alterations enhance lysosomal function and sup-
port increased autophagic flux. First, we validated the RNA-seq
results by conducting RT-qPCR analyses, which showed that
BRD4 knockdown significantly upregulated a number of lyso-
some genes involved in proteolysis, glycan degradation, and
lysosome biogenesis (Figure 3A). Consistent with this, we
observed an increase in lysosomal protein levels, including lyso-
somal-associated membrane protein 1 (LAMP1), LAMP2, acid
sphingomyelinase (ASM), a-glucosidase (GAA), and heavy chain
of mature cathepsin B (CTSB HC) and cathepsin D (CTSD HC)
(Figure 3B; Figure S3A). Staining of lysosomal compartments
with anti-LAMP1 antibody and LysoTracker red also revealed
an expanded lysosomal area in BRD4 knockdown cells (Figures
3C and 3D, upper panels). To assess the activity of lysosomal en-
zymes, we employed the use of Magic Red CTSB, a CTSB sub-
strate that produces a cresyl violet fluorophore upon proteolytic
BC
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Figure 2. BRD4 Is a Negative Regulator of Autophagy Gene Expression
(A and B) KP-4 cells transfected with control or BRD4 siRNA were subjected to RNA-seq and gene ontology analyses (A) and RT-qPCR analysis (B).
(C) RT-qPCR analysis of KP-4 cells treated with DMSO, 500 nM JQ1, 500 nM I-BET151, or 500 nM OTX015 for 9 hr.
(D) RT-qPCR analysis of KP-4 cells treated with 500 nM JQ1 for the indicated time.
(E) RT-qPCR analysis of KP-4 cells overexpressing BRD4.
All data are shown asmean ± SD. In (A)–(D), n = 3 independent experiments; in (E), data are representative of two independent experiments performed in triplicate.
*p < 0.01, **p < 0.05. See also Figure S2.cleavage. As shown in Figure 3D’s lower panels, a significant in-
crease in CTSB substrate cleavage was seen in BRD4 knock-
down cells. In addition, we also observed increased enzymatic
activity of b-hexosaminidase, a lysosomal enzyme that catalyzes
the hydrolysis of ganglioside monosialic 2, in BRD4 knockdown
cells (Figure 3E). These results indicate that not only autophagic
flux, but also lysosomal biogenesis and function are enhancedby BRD4 knockdown. Furthermore, we also observed upregula-
tion of autophagy and lysosomal gene expression upon BRD4-
NUT inhibition by NUT siRNA and JQ1 and an increase in
lysosomal protein levels and LysoTracker+ acidic compartments
in BRD4-NUT knockdownNMCcells (Figures 3F and 3G; Figures
S3B and S3C), suggesting that BRD4-NUT also suppresses the
autophagy-lysosome pathway in NMC.Molecular Cell 66, 517–532, May 18, 2017 521
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Activation of the autophagy-lysosome pathway in BRD4
knockdown cells is reminiscent of the phenotype observed by
activation of TFEB (Settembre et al., 2011). We therefore tested
the possibility that BRD4 knockdown stimulates autophagy
through activation of TFEB and its related members TFE3 and
MITF. However, BRD4 knockdown cells were capable of acti-
vating autophagy in the absence of TFEB (Figures S3D–S3F).
Furthermore, BRD4 knockdown still activated autophagy and
lysosome gene transcription and enhanced autophagic flux in
cells where all MiT/TFE members (TFEB, TFE3, and MITF) were
simultaneously silenced (Figure 3H; Figures S3G–S3J), indi-
cating that BRD4 regulates autophagy independently of MiT/
TFE transcription factors.
BRD4 Is Recruited to Autophagy Gene Promoters and Its
Dissociation Leads to Transcriptional Activation of
Autophagy Genes
We next examined the molecular mechanism by which BRD4 re-
presses autophagy and lysosome gene expression. Given that
BET inhibitor dissociates BRD4 from acetylated histones and
rapidly upregulates autophagy genes (Figure 2D), we hypothe-
sized that BRD4 binds to acetylated histones at autophagy and
lysosome gene promoter regions. Indeed, BRD4 was found at
autophagy and lysosome gene promoter regions, and its enrich-
ment was reduced after JQ1 treatment (Figures S4A and S4B).
BRD4 occupation at autophagy and lysosome gene promoters
was also significantly decreased during starvation, and this
BRD4 dissociation was correlated with upregulation of gene
expression (Figures 4A and 4B).
Interestingly, histone H4 lysine 16 (H4K16) acetylation that is
recognized by BRD4 (Zippo et al., 2009) is downregulated
upon autophagic stimulation (F€ullgrabe et al., 2013). H4K16
acetylation and its acetyltransferase human males absent on
the first (hMOF) have been described as both positive and nega-
tive regulators of autophagy (F€ullgrabe et al., 2013; Hale et al.,
2016). Therefore, we tested whether BRD4 recruitment is regu-
lated by hMOF. CRISPR/CRISPR-associated protein 9 (Cas9)-
mediated editing of hMOF efficiently reduced hMOF protein
levels and H4K16Ac status at autophagy gene promoters
(Figures S4C and S4D). Depletion of hMOF also caused BRD4
dissociation from autophagy gene promoters, upregulation of
autophagy gene expression, and increased LC3 lipidation (Fig-
ure 4C; Figures S4E andS4F). Consistent with the previous study
(F€ullgrabe et al., 2013), H4K16Ac declined upon starvation (Fig-
ure 4D), implying that BRD4 dissociation is attributed to H4K16
deacetylation in response to starvation. However, analysis of
hMOF protein levels revealed that they did not change duringFigure 3. BRD4 Knockdown Enhances Lysosomal Function
(A) RT-qPCR analysis of KP-4 cells transfected with control or BRD4 siRNA.
(B–D) KP-4 cells transfected with BRD4 siRNA were subjected to western blot an
antibody (C), LysoTracker Red (100 nM, 2 hr) (D, upper panels), and Magic Red
CTSB+ area normalized to cell number is shown (C, CON: n = 115 cells, BRD4: n =
D lower, CON: n = 164 cells, BRD4 1: n = 109 cells, BRD4 2: n = 53 cells). Scale
(E) Hexosaminidase activity was measured using lysates from control and BRD4
(F and G) RT-qPCR analysis of TY-82 cells transfected with NUT siRNA for 72 hr
(H) KP-4 cells were transfected with BRD4 and/or MiT/TFE (TFEB, TFE3, MITF) s
All data are shown as mean ± SD. In (A) and (F), n = 3 independent experiments
independent experiments performed in triplicate. *p < 0.01, **p < 0.05. See alsostarvation (Figure S4G). As a result, we hypothesized instead
that the decrease in H4K16 acetylation and subsequent BRD4
dissociation during starvation may be driven by the deacetylase
Sirtuin 1 (SIRT1) (Vaquero et al., 2007). In line with this hypothe-
sis, H4K16 deacetylation and BRD4 dissociation by starvation
were not seen in cells infected with Cas9/single-guide RNA
(sgRNA) targeting SIRT1 (Figure 4E; Figure S4H). In addition,
SIRT1 depletion suppressed starvation-induced autophagy
gene expression and LC3 lipidation (Figure 4F; Figure S4I),
underscoring the importance of this enzyme in this response.
It is known that SIRT1 is activated by nutrient deprivation via its
dissociation from the inhibitory molecule Deleted in Breast Can-
cer protein 1 (DBC1) and an increase in nicotinamide adenine
dinucleotide (NAD+) levels in a manner dependent on AMP-acti-
vated protein kinase (AMPK) (Canto´ et al., 2009; Chang et al.,
2015). As expected, AMPK phosphorylation at Thr172, which is
required for its activation, increased during nutrient starvation
(Figure S4J). Consistent with these observations, we found that
BRD4 forms a complex with SIRT1 and DBC1 and that starvation
disrupts the SIRT1-DBC1 interaction (Figures S4K and S4L). The
dissociation of this interaction was not observed in cells treated
with AMPK inhibitor Compound C and infected with Cas9/
sgRNAs targeting AMPKa catalytic subunits (Figure 4G; Fig-
ure S4M). Moreover, disruption of AMPKa genes prevented
BRD4 dissociation from autophagy gene promoters in response
to starvation (Figure S4N). As a consequence, AMPK inhibition
blocked autophagy gene expression and autophagic flux
induced by starvation (Figure 4H; Figures S4O and S4P). Collec-
tively, these results detail a signaling cascade from nutrient
deprivation to de-repression of autophagy gene transcription,
which involves the disruption of SIRT1-DBC1 interaction by
AMPK and SIRT1-mediated BRD4 dissociation from autophagy
gene promoters.
BRD4 Represses Autophagy Gene Expression through
Binding to G9a
In contrast to its well-established role as a positive transcrip-
tional regulator of genes involved in cell growth (Shi and Vakoc,
2014), BRD4 represses expression of a subset of autophagy
genes. We therefore investigated the molecular mechanism by
which BRD4 suppresses autophagy gene expression. From pre-
vious interactome analyses of BRD4 (Dawson et al., 2011), we
searched for BRD4 interacting protein(s) that are known to be
involved in gene repression. Different from the majority of inter-
acting proteins, histone lysine methyltransferase G9a has been
shown to both promote and repress transcription by catalyzing
mono- and di-methylation of histone H3 at lysine 9 (H3K9),alysis with antibodies against lysosomal proteins (B) and stained with LAMP1
CTSB (1 hr) (D, lower panels). Area of LAMP1+, LysoTracker+, and Magic Red
130 cells; D upper, CON: n = 66 cells, BRD4 1: n = 52 cells, BRD4 2: n = 50 cells;
bars, 50 mm.
knockdown KP-4 cells.
(F) or treated with 500 nM JQ1 for 9 hr (G).
iRNAs and treated with 10 mM CQ for 4 hr.
. In (E), n = 4 independent experiments. In (G), data are representative of two
Figure S3.
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respectively (Shinkai and Tachibana, 2011). We first confirmed
the interaction between BRD4 and G9a by reciprocal co-immu-
noprecipitation (Figure 5A). G9a interacted with the long and
short isoforms of BRD4 (Figure S5A), which is consistent with
our observations that both isoforms contribute to autophagy
repression (Figure S1F). Importantly, we observed that the inter-
action between BRD4 and G9a was disrupted by starvation
(Figure 5B). In addition, G9a recruitment to autophagy gene pro-
moters was abolished by JQ1 treatment and BRD4 knockdown
(Figures 5C and 5D; Figures S5B and S5C). Consequently,
H3K9diMe status was also reduced in these settings (Figures
5E and 5F). Consistent with a functional role in the regulation
of autophagy, G9a silencing upregulated autophagy gene
expression and enhanced autophagic flux (Figures 5G and 5H;
Figures S5D and S5E). Furthermore, simultaneous knockdown
of BRD4 and G9a did not cause further accumulation of LC3II
and autophagy gene transcripts (Figures 5G and 5H; Figure S5E),
and G9a silencing largely abolished autophagy suppression by
BRD4 overexpression (Figure 5I; Figure S5F), suggesting that
BRD4 and G9a act on the same pathway. In addition, we found
that autophagy regulation by H4K16 acetylation and G9a is also
conserved in NMC. Depletion of hMOF decreased H4K16 acet-
ylation and increased LC3II levels in TY-82 cells (Figures S5G–
S5I). Starvation led to a SIRT1-dependent H4K16 deacetylation
at autophagy gene promoters (Figure S5J). BRD4-NUT interacts
with G9a, and G9a silencing promoted LC3 lipidation (Figures
S5K and S6L), implying that, like BRD4, BRD4-NUT suppresses
autophagy through G9a.
BRD4 Knockdown Modulates Specific Types of
Autophagy
Bulk degradation of cytoplasmic components by autophagy,
termed bulk autophagy, is thought to feed energy sources during
nutrient shortage, whereas degradation of specific substrates,
such as protein aggregates, damaged mitochondria and patho-
gens, called selective autophagy, serves as an intracellular qual-
ity control mechanism (Khaminets et al., 2016; Rabinowitz and
White, 2010). We were therefore interested in understanding
the contribution of BRD4 to the control of stimulus-dependent
and selective autophagy.
In the first instance, we examined starvation- and rapamycin-
induced autophagy and found that they were augmented by
BRD4 silencing (Figures 6A and 6B; Figures S6A and S6B).
Reduction of both LC3I and II after 2 hr of starvation in BRD4
knockdown cells suggests enhanced LC3I conversion to
LC3II and subsequent degradation (Figure 6A; Figure S6A).
Conversely, BRD4 overexpression suppressed LC3I conversion
to LC3II induced by starvation and rapamycin (Figure S6C). InFigure 4. Starvation Leads to BRD4 Dissociation from Autophagy Gen
(A and B) KP-4 cells were starved for 4 hr followed by chromatin immunoprecipi
(C) KP-4 cells infected with Cas9/hMOF sgRNA were subjected to ChIP assay w
(D) KP-4 cells were starved for 4 hr followed by ChIP assay with H4K16Ac antibo
(E and F) KP-4 cells infected with Cas9/SIRT1 sgRNAwere starved for 4 hr followed
shows efficient SIRT1 depletion in Cas9/SIRT1 sgRNA-infected cells.
(G and H) KP-4 cells infected with Cas9/AMPKa1 and a2 sgRNAs were starved fo
analysis (H).
All data are shown as mean ± SD. In (A)–(F) and (H), n = 3 independent experimeaddition, BRD4 knockdown further activated autophagy induced
by glucose starvation, hypoxia, trehalose, and oncogenic Ras
mutant (Figures 6C–6F; Figures S6D–S6G). Similarly, TFEB and
TFE3-mediated autophagy activation was also augmented by
BRD4 and G9a silencing (Figures S6H and S6I). We next deter-
mined whether BRD4 knockdown would promote the autopha-
gic degradation of protein aggregates (aggrephagy). To test
this, we analyzed aggregates caused by mutant Huntingtin
(HTT) and found that BRD4 silencing promoted the degradation
of poly-glutamine (Q)-expanded HTT (HTT 94Q) (Figure 6G).
Conversely, BRD4 overexpression exacerbated the accumula-
tion of HTT 94Q in the insoluble fraction (Figure S6J). Similar to
the previous reports (Williams et al., 2008), induction of polyQ-
expanded HTT caused a reduction in cell number, and BRD4
knockdown ameliorated this effect (Figure S6K).
In contrast, modulation of BRD4 did not promote or prevent the
clearanceofSalmonella entericaserovarTyphimuriumbyxenoph-
agy (Figure 6H; Figure S6L) or mitochondria by mitophagy (Fig-
ure 6I; Figures S6M and S6N). In fact, we actually observed an
accumulation ofmitochondrial proteins inBRD4knockdowncells,
whichmay be due to transcriptional upregulation ofmitochondrial
genes as recently described (Barrow et al., 2016). A similar effect
was also observed with p62/SQSTM1 mRNA and protein levels
upon BRD4 knockdown (Figure 2B; Figure S6O), thereby compli-
cating its utility as a marker of autophagic activity modulated by
BRD4. Inconclusion, our collective results showthatBRD4knock-
down affects some, but not all, types of autophagy, indicating that
it is a regulator of this response in specific contexts.
BRD4 Knockdown Sustains mTOR Activity during
Starvation and Confers Resistance to Starvation-
Induced Cell Death
Autophagic degradation of intracellular proteins produces amino
acids, leading to activation of the amino acid sensor mechanistic
target of rapamycin complex1 (mTORC1), and these nutrient
sources can be used to maintain cell survival during periods of
starvation (Perera et al., 2015; Rabinowitz and White, 2010).
We observed that BRD4 knockdown sustained the phosphoryla-
tion status of S6K, a substrate of mTORC1 and established
readout of mTORC1 activity (Perera et al., 2015), during amino
acid starvation (Figure 7A). This sustained S6K phosphorylation
was abolished by CQ and CRISPR/Cas9-mediated ATG5 gene
disruption (Figures 7B and 7C), suggesting that BRD4 knock-
down activates mTORC1 through the autophagy-lysosome
pathway during amino acid shortage. Therefore, we next
examined whether autophagy activation by BRD4 knockdown
affects cell growth and cell survival during nutrient deprivation.
As reported previously (Shi and Vakoc, 2014; Zuber et al.,e Promoters
tation (ChIP) assay with BRD4 antibody (A) and RT-qPCR analysis (B).
ith BRD4 antibody.
dy.
by ChIP assaywith BRD4 antibody (E) and RT-qPCR analysis (F). Western blot
r 4 hr followed by immunoprecipitation with DBC1 antibody (G) and RT-qPCR
nts. *p < 0.01, **p < 0.05, N.S., no significance. See also Figure S4.
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2011), BRD4 knockdown caused downregulation of c-Myc,
altered cell cycle gene expression, and decreased cell prolifera-
tion due to cell cycle retardation under nutrient-replete condi-
tions (Figures S7A–S7D). We found, however, that this growth
retardation was caused independently of autophagic activity
(Figures S7E and S7F). In contrast to these effects on cell growth,
we found that starvation-induced cell death was significantly
suppressed in BRD4 knockdown cells, and this protective effect
was abolished by ATG5 gene disruption and CQ treatment (Fig-
ures 7D–7G; Figure S7G). These data therefore suggest that the
modulation of autophagy by BRD4 inhibition maintains cell sur-
vival under starvation conditions by providing nutrient source.
DISCUSSION
In this study, we show that a series of autophagic processes,
including autophagosome formation, fusion of autophagosomes
with lysosomes, and lysosome biogenesis and function, is tran-
scriptionally repressed by BRD4. BRD4 knockdown upregulates
a subset of autophagy and lysosome genes, which in turn en-
hances autophagic flux and lysosome biogenesis and activity.
Interestingly, the effect of this transcriptional program only
affects certain forms of autophagy. We found that knockdown
of BRD4 promoted autophagy induced by stimuli, such as
nutrient deprivation, rapamycin, and protein aggregates, but
this did not affect the autophagic removal of mitochondria or
bacteria. This indicates that the program is selectively engaged,
adding another layer of complexity to the control of this ubiqui-
tous and yet multifaceted process.
As different types of selective autophagy utilize their desig-
nated receptors to recruit the cargos, we examined whether
the aggrephagy receptor(s) are specifically upregulated by
BRD4 and found that the expression of p62 and Optineurin
increased upon BRD4 knockdown (Figure 2B; Figure S7H). How-
ever, these receptors capture ubiquitinated mitochondria and
pathogens, as well as protein aggregates (Khaminets et al.,
2016); therefore, these alterations do not provide a mechanistic
explanation for the autophagy specificity conferred by BRD4
knockdown. Since mechanisms of selective autophagy are not
fully elucidated, the future identification of selective auto-
phagy-specific regulators will help solve this question.
In the case of autophagy induced by nutrient availability, it is
already clear that the process is orchestrated by different mech-
anisms. The acute response to nutrient deprivation includes
nutrient sensing by mTORC1 and AMPK and activation of the
UNC-51-like kinase (ULK) and class III phosphatidylinositol-3 ki-
nase (PI3K) complexes. This subsequently leads to the formation
of a PI3P-enriched membrane compartment, recruitment of
the ATG12-5-16L1 complex, and LC3 lipidation (Lamb et al.,Figure 5. BRD4 Represses Autophagy Gene Expression through G9a
(A) Cell extracts from KP-4 cells were subjected to immunoprecipitation with G9
(B) KP-4 cells were starved for 4 hr followed by immunoprecipitation with BRD4
(C–F) KP-4 cells were treated with 500 nM JQ1 for 9 hr (C and E). KP-4 cells harbor
(DOX) for 4 days (D and F). ChIP assays were performed using G9a (C and D) an
(G and H) KP-4 cells infected with shRNA targeting G9a were transfected with B
(I) KP-4 cells overexpressing BRD4 were infected with shRNA targeting G9a.
All data are shown as mean ± SD. In (C)–(G), n = 3 independent experiments. *p2013). More recently, it has become clear that the transcriptional
activation of autophagy and lysosome genes plays an important
role in prolonged autophagy (F€ullgrabe et al., 2014). Although the
link between nutrient sensing by mTORC1 and TFEB-mediated
autophagy/lysosome gene activation is now well recognized,
other signaling pathways that mediate the nutrient regulation of
autophagy genes are not fully understood. In this regard, we
report that a signaling cascade consisting of two nutrient sensor
molecules—AMPK and SIRT1—integrate the nutrient status of
the cell to autophagy gene regulation via BRD4. Nutrient depriva-
tion causes the dissociation of SIRT1 from its inhibitory molecule
DBC1 in an AMPK-dependent manner and may also activate
SIRT1 via an increase in NAD+/NADH ratio (Canto´ et al., 2009),
which in turn leads to SIRT1-mediated BRD4 dissociation from
autophagy gene promoters and de-repression of autophagy
gene expression. Our findings suggest that BRD4 suppresses
autophagy and lysosome gene expression under nutrient-
replete conditions to prevent excess autophagy, and BRD4
dissociation allows cells to maintain autophagic activity during
prolonged nutrient shortage. Interestingly, a recent report
showing that JQ1 increases LC3 lipidation and autophagosome
formation implicates the involvement of BET proteins in auto-
phagy regulation (Jang et al., 2016). Importantly, however, the
detailed mechanism by which JQ1 modulates autophagy and
the molecule that mediates this effect were not explored.
Currently, TFEB is thought to be a ‘‘master’’ regulator of auto-
phagy and lysosome gene transcription (Settembre et al., 2011).
Importantly, BRD4 inhibition activates autophagy in the absence
of TFEB and its related molecules TFE3 and MITF. This observa-
tion suggests that BRD4 orchestrates a distinct transcriptional
program and is therefore another crucial regulator of autophagy
and lysosome gene expression. Interestingly, a recent report has
shown that AMPK activates TFEB-mediated transcription by
inducing the transcriptional coactivator, Coactivator associated
arginine (R) methyltransferase 1 (CARM1) (Shin et al., 2016).
These findings, taken together, suggest that AMPK activation
upon nutrient deprivation stimulates TFEB-mediated transcrip-
tion and suppresses BRD4 function to cooperatively activate
the autophagy-lysosome pathway.
BRD4 has been proposed as a positive regulator of transcrip-
tion that bridges histone acetylation and transcriptional regula-
tors such as P-TEFb and the Mediator complex (Shi and Vakoc,
2014). We observed, as previously reported, that this positive
effect on transcription is particularly important for the regulation
of genes involved in the promotion of cell growth (Zuber et al.,
2011), and so it is interesting that BRD4 at the same time recip-
rocally represses genes involved in major catabolic processes at
the lysosome and vice versa. Interestingly, although this is not
the first report to show that BRD4 functions as a transcriptionala (upper) and BRD4 (lower) antibodies.
antibody.
ing inducible control or BRD4 shRNAwere treated with 500 ng/mL doxycycline
d H3K9diMe (E and F) antibodies.
RD4 siRNA followed by RT-qPCR (G) and western blot (H).
< 0.01, **p < 0.05, N.S., no significance. See also Figure S5.
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Figure 6. Effect of BRD4 Silencing on Stimulus-Dependent and Selective Autophagy
(A–F) Cells transfected with BRD4 siRNAwere starved for 1–5 hr (KP-4 cells, A), treated with 500 nM rapamycin for 24 hr (KP-4 cells, B), starved of glucose for 4 hr
(KP-4 cells, C), cultured under hypoxic (1%O2) conditions for 48 hr (SUIT2 cells, D), treated with 100 mM Trehalose for 4 hr (KP-4 cells, E), or treated with 500 nM
4-Hydroxytamoxifen (4-OHT) for 48 hr (IMR90 ER-HRas G12V cells, F).
(G) KP-4 cells harboring rtTA and Tre-tight-HTT Q94-CFP were transfected with BRD4 siRNA. At 12 hr after transfection, cells were treated with 1 mg/mL DOX for
10 hr. At 48 hr after removal of DOX, cells were separated into Triton X-100 soluble and insoluble fractions.
(H) KP-4cells transfectedwithBRD4siRNAwere infectedwithSalmonella enterica serovar Typhimurium. Thenumber ofSalmonellawasdeterminedbyperforming
colony-forming unit assays at 2, 6, and 8 hr after infection and normalized to the numbers at 2 hr. Data are shown asmean ± SEM; n = 4 independent experiments.
(I) KP-4 cells expressing YFP-parkin were transfected with BRD4 siRNA followed by treatment with 1 mM Antimycin A and 1 mM Oligomycin for 8 hr.
See also Figure S6.
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Figure 7. BRD4 Knockdown Sustains mTOR Activity during Starvation and Confers Resistance to Starvation-Induced Cell Death
(A and B) KP-4 cells transfected with BRD4 siRNAwere starved of amino acids (A). Cells pre-treated with CQ (10 mM, 4 hr) were subjected to amino acid starvation
for 2 hr in the presence of CQ (B).
(C) KP-4 cells infected with Cas9/ATG5 sgRNA were transfected with BRD4 siRNA and subjected to amino acid starvation for 2 hr.
(legend continued on next page)
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repressor, the mechanisms behind this effect were largely un-
known (Barrow et al., 2016). We show that BRD4 is recruited
to autophagy and lysosome gene promoter regions and interacts
with G9a that deposits a repressive H3K9diMe mark. However,
our finding that G9a knockdown largely, but not completely,
abrogates autophagy repression by BRD4 overexpression im-
plies that there are other mechanism(s) that mediate the auto-
phagy suppression by BRD4. Different transcriptional activators
(i.e., FOXO family and p53 family), repressors (i.e., ZKSCAN3
and FOXK), and histone modifications (i.e., H3K27triMe and
H2BK120Ub) are also involved in the transcriptional regulation
of autophagy (Baek and Kim, 2017; F€ullgrabe et al., 2016). There-
fore, it remains possible that BRD4 affects the recruitment of
these transcription factors and histone-modifying enzymes to
suppress autophagy gene expression.
Modulation of autophagic activity is thought to be a potential
therapeutic strategy for various diseases, including neuronal
degeneration, infectious diseases, and cancer (Rubinsztein
et al., 2012). In this regard, identification of druggable autophagy
regulators would be an attractive strategy to treat these dis-
eases. BET inhibitors exhibit anti-tumor effects in various types
of cancers and have been tested in phase one and two clinical
trials (Wang and Filippakopoulos, 2015). Our findings also poten-
tially indicate that BET inhibitors may have beneficial effects in
diseases, such as neurodegeneration, where promotion of auto-
phagy is being explored for therapy.
There has beenmuch interest in whether autophagy represses
or promotes tumor development (Galluzzi et al., 2015) and so the
fact that the product of a chromosomal translocation considered
to be the driver of NMC is a repressor of autophagy is an inter-
esting discovery. Interestingly, we found that, in NMC cells,
BRD4 expressed from the unaffected allele has little contribution
to the regulation of autophagy, indicating a dominant role of
BRD4-NUT in autophagy repression. How this enhanced repres-
sion is achieved and how much, if at all, the repression of auto-
phagy is a contributing factor in the development of NMC are
beyond the scope of this current study but undoubtedly worthy
of future investigation.
Taken together, the findings we present here detail a mecha-
nism of transcriptional regulation of autophagy and lysosome
function. The mechanism facilitates some forms of autophagy,
but not others, and this therefore highlights an additional control
point of autophagy regulation that may be relevant to various
forms of human disease.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal anti-BRD4 (clone E2A7X) (human
specific) (long isoform)
Cell Signaling Technology Cat#: 13440S
Rabbit monoclonal anti-NUT (clone C52B1) Cell Signaling Technology Cat#: 3625S; RRID: AB_2066833
Rabbit monoclonal anti-G9a (EHMT2/KMT1C)
(clone C6H3)
Cell Signaling Technology Cat#: 3306S; RRID: AB_2097647
Rabbit monoclonal anti-SIRT1 (clone D1D7) Cell Signaling Technology Cat#: 9475P; RRID: AB_2617130
Mouse monoclonal anti-DBC1 (clone 3G4) Cell Signaling Technology Cat#: 5857S; RRID: AB_10838138
Rabbit monoclonal anti-AMPKa pT172 Cell Signaling Technology Cat#: 2535S; RRID: AB_331250
Mouse monoclonal anti-AMPKa1/a2 Cell Signaling Technology Cat#: 2793S; RRID: AB_915794
Rabbit polyclonal anti-LC3B Cell Signaling Technology Cat#: 2775S; RRID: AB_915950
Rabbit monoclonal anti-LC3B (clone D11) Cell Signaling Technology Cat#: 3868S; RRID: AB_2137707
Rabbit polyclonal anti-TFEB Cell Signaling Technology Cat#: 4240S; RRID: AB_11220225
Rabbit monoclonal anti-LAMP1 (clone D2D11) Cell Signaling Technology Cat#: 9091P
Rabbit polyclonal anti-Cathepsin D Cell Signaling Technology Cat#: 2284S; RRID: AB_10694258
Rabbit polyclonal anti-ASM Cell Signaling Technology Cat# 3687S; RRID: AB_1904135
Rabbit monoclonal anti-Cathepsin B (clone D1C7Y) Cell Signaling Technology Cat#: 31718S
Rabbit monoclonal anti-ATG5 (clone D5F5U) Cell Signaling Technology Cat#: 12994S
Rabbit monoclonal anti-p70 S6K pT389 (clone 108D2) Cell Signaling Technology Cat#: 9234S; RRID: AB_2269803
Rabbit monoclonal anti-p70 S6K (clone 49D7) Cell Signaling Technology Cat#: 2708S; RRID: AB_390722
Rabbit monoclonal anti-Acetyl-Histone H4 (Lys16)
(clone E2B8W)
Cell Signaling Technology Cat#:13534S
Mouse monoclonal anti-Histone H4 (clone L64C1) Cell Signaling Technology Cat#: 2935P; RRID: AB_1147658
Rabbit monoclonal anti-c-Myc (clone D84C12) Cell Signaling Technology Cat#: 5605S; RRID: AB_1903938
Rabbit monoclonal anti-CDK9 (clone C12F7) Cell Signaling Technology Cat#: 2316T; RRID: AB_2291505
Rabbit monoclonal anti-GFP (clone D5.1) Cell Signaling Technology Cat#: 2956S; RRID: AB_1196615
Rabbit polyclonal anti-TFE3 Cell Signaling Technology Cat#: 14779S
Normal rabbit IgG Cell Signaling Technology Cat#: 2729S; RRID: AB_1031062
Mouse IgG1 isotype control G3A1 Cell Signaling Technology Cat#: 5415S; RRID: AB_10829607
Rabbit monoclonal anti-BRD4 (clone EPR5150(2))
(human and mouse) (long and short isoforms)
Abcam Cat#: ab128874; RRID: AB_11145462
Mouse monoclonal anti-GAPDH Abcam Cat#: ab9484; RRID: AB_307274
Rabbit polyclonal anti-b-actin Abcam Cat#: ab8227; RRID: AB_2305186
Rabbit polyclonal anti-G9a (EHMT2/KMT1C) Abcam Cat#: ab133482
Mouse monoclonal anti-Histone H3 (di methyl K9) Abcam Cat#: ab1220; RRID: AB_449854
Rabbit polyclonal anti-GAA (clone EPR4716(2)) Abcam Cat#: ab137068
Mouse monoclonal Membrane Integrity WB
Antibody Cocktail
Abcam Cat#: ab110414
Rabbit polyclonal anti-BRD4 (human and mouse)
(long isoform)
Bethyl Laboratories Cat#: A301-985A50; RRID: AB_2631449
Rabbit polyclonal anti-BRD2 Bethyl Laboratories Cat#: A302-583A; RRID: AB_2034829
Rabbit polyclonal anti-BRD3 Bethyl Laboratories Cat#: A302-368A; RRID: AB_1907251
Rabbit polyclonal anti-hMOF (MYST1/KAT8) Bethyl Laboratories Cat#: A300-992A; RRID: AB_805802
Rabbit polyclonal anti-Acetyl-Histone H4 (Lys16) Millipore Cat#: 07-329; RRID: AB_310525
Rabbit polyclonal anti-Acetyl-Histone H4 (Lys16) Active Motif Cat#: 39167
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Mouse monoclonal anti-LAMP2/CD107b BD Biosciences Cat#: 555803; RRID: AB_396137
Mouse monoclonal anti-p62 BD Biosciences Cat#: 610833; RRID: AB_398152
Mouse monoclonal anti-GFP Covance Cat#: MMS-118P-200; RRID: AB_10063778
Goat polyclonal anti-LaminA/C Santa Cruz Cat#: sc-6215; RRID: AB_648152
Goat polyclonal anti-HSP90b Santa Cruz Cat#: sc-1057; RRID: AB_2121392
Mouse monoclonal anti-FLAG (clone M2) Sigma-Aldrich Cat#: F1804; RRID: AB_262044
Mouse monoclonal anti-V5 Invitrogen Cat#: 46-0705
Mouse monoclonal anti-WIPI2 Bio-Rad Cat#: MCA5780GA; RRID: AB_10845951
Mouse monoclonal anti-LC3 NanoTools Cat#: 0231-100/LC3-5F10
Bacterial and Virus Strains
Salmonella enterica serovar Typhimurium
(strain 12023)
David Holden Lab (Imperial
College London)
N/A
Chemicals, Peptides, and Recombinant Proteins
Chloroquine Sigma-Aldrich Cat#: C6628
Doxycycline Sigma-Aldrich Cat#: D9891
Antimycin A Sigma-Aldrich Cat#: A8674
Oligomycin Sigma-Aldrich Cat#: O4876
D-(+)-Trehalose dihydrate Sigma-Aldrich Cat#: T0167
4-Hydroxytamoxifen Sigma-Aldrich Cat#: H7904
(+)-JQ1 TOCRIS Cat#: 4499
I-BET151 TOCRIS Cat#: 4650
OTX015 Cayman Cat#: 15947
Compound C EMD Millipore Cat#: 171264
Rapamycin LC Laboratories Cat#: R-5000
ARV-825 Chemietek Cat#: CT-ARV825
LysoTracker red DND-99 Thermo Fisher Scientific Cat# L7528
Magic Red Cathepsin B ImmunoChemistry Technologies Cat#: 938
Hoechst33342 Thermo Fisher Scientific Cat#: H3570
Critical Commercial Assays
TruSeq RNA Sample Prep Kit v2 Illumina Cat#: RS-122-2001
Click-iT EdU Flow Cytometry Assay Kit Thermo Fisher Scientific Cat#: C10633
Deposited Data
Raw and processed data of the RNA-seq This paper GEO: GSE90444
Full scans of western blot data and original microscopy
images
This paper Mendeley Data: http://dx.doi.org/10.
17632/ksz4pmwkdb.1
Experimental Models: Cell Lines
Human: KP-4 RIKEN RCB1005
Human: PA-TU-8902 DMSZ ACC-179
Human: SUIT2 JCRB JCRB1094
Human: PA-TU-8988T DMSZ ACC-162
Human: hTERT-HPNE ATCC CRL-4023
Human: IMR90 ER-HRas G12V Peter D. Adams Lab (Cancer
Research UK Beatson Institute)
N/A
Human: HEK293T ATCC CRL-3216
Human: PK-1 RIKEN RCB1972
Human: TY-82 JCRB JCRB1330
Human: Phoenix-AMPHO ATCC CRL-3213
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Experimental Models: Organisms/Strains
Mouse: CAGs-rtTA3 Scott W. Lowe Lab (Memorial
Sloan Kettering Cancer Center)
Premsrirut et al., 2011 (also available from
the Jackson Laboratory, Stock #: 016532)
Mouse: TRE-shRen Scott W. Lowe Lab N/A
Mouse: TRE-shBRD4 Scott W. Lowe Lab N/A
Mouse: C57BL/6J The Jackson Laboratory Stock #: 000664
Oligonucleotides
siRNAs, see the Table S1 N/A N/A
pPCR primers, See the Table S2 N/A N/A
Recombinant DNA
pBabe-puro Morgenstern and Land, 1990 Addgene plasmid # 1764
pRetrox-tight-puro-HA-BRD4 MRC Protein Phosphorylation
and Ubiquitylation Unit
Cat#: DU46347
pBabe-puro-human BRD4 long variant This paper N/A
pLenti-puro Guan et al., 2011 Addgene plasmid # 39481
pLenti-puro-human BRD4 long variant This paper N/A
pEGFP-C1+mRFP-LC3 Tamotsu Yoshimori Lab (Osaka
University)
Kimura et al., 2007
pBabe-puro-mRFP-GFP-LC3 This paper N/A
pLZRS-YFP-Parkin Baudot et al., 2015 N/A
pcDNA3 Invitrogen N/A
pcDNA3-human BRD4 short variant This paper N/A
pLenti6-MK1-EHMT2 (G9a)-V5 (human G9a long
variant)
Addgene Addgene plasmid # 31113
pTRE-tight Clontech Cat#: 631059
pTRE-tight-Htt94Q-CFP Maynard et al., 2009 Addgene plasmid #23966
pMA2640 Alexeyev et al., 2010 Addgene plasmid #25434
pFlag-CMV2-Brd4 (1-1362) (human BRD4 long variant) Bisgrove et al., 2007 Addgene plasmid #22304, discontinued
due to reason other than plasmid issue
psPAX2 Addgene Addgene plasmid #12260
pMD2.G Addgene Addgene plasmid #12259
pMXs-puro GFP-p62 Itakura and Mizushima, 2011 Addgene plasmid #38277
pEGFP-N1 Clontech Cat#: 6085-1
pEGFP-N1-TFEB Roczniak-Ferguson et al., 2012 Addgene plasmid #38119
pEGFP-N1-TFE3 Roczniak-Ferguson et al., 2012 Addgene plasmid #38120
pEGFP-N1-MITF-A Roczniak-Ferguson et al., 2012 Addgene plasmid #38132
pEGFP-Q74 Narain et al., 1999 Addgene plasmid # 40262
pLVX-TetOne-Puro Clontech Cat#: 631849
pLVX-TetOne-Puro-GFP-HTT exon1 Q74 This paper N/A
lentiCRISPR v2 Sanjana et al., 2014 Addgene plasmid #52961
lentiCRISPR v2-human hMOF/KAT8 #1 This paper N/A
lentiCRISPR v2-human hMOF/KAT8 #2 This paper N/A
lentiCRISPR v2-human SIRT1 This paper N/A
lentiCRISPR v2-human AMPKa1/PRKAA1 This paper N/A
lentiCRISPR v2-human AMPKa2/PRKAA2 This paper N/A
lentiCRISPR v2-human ATG5 This paper N/A
lentiCRISPR v2-non-targeting control (NTC) This paper N/A
pLKO.1-non-targeting control (NTC) Sigma-Aldrich Cat#: SHC002
pLKO.1-human G9a shRNA #1 Dharmacon Cat#: TRCN0000115670
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pLKO.1-human G9a shRNA #2 Dharmacon Cat#: TRCN0000115668
pTRIPZ-non-targeting control (NTC) Dharmacon Cat#: RHS4743
pTRIPZ-human BRD4 shRNA (targeting short and long
variants)
Dharmacon Cat#: V3THS326487
Software and Algorithms
ImageJ64 NIH https://imagej.nih.gov/ij/
CellProfiler Anne Carpenter Lab (Broad
Institute)
http://cellprofiler.org
Optimized CRISPR Design Feng Zhang Lab (MIT) http://crispr.mit.edu
FastQC Babraham Bioinformatics https://www.bioinformatics.babraham.
ac.uk/projects/fastqc/
FastQ Screen Babraham Bioinformatics http://www.bioinformatics.babraham.
ac.uk/projects/fastq_screen/
TopHat2 v.2.0.10 Kim et al., 2013 https://ccb.jhu.edu/software/tophat/
index.shtml
Bowtie v.2.1.0 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
HTSeq v.0.5.4p3 Simon Anders (EMBL
Heidelberg)
http://www-huber.embl.de/users/
anders/HTSeq/doc/overview.html
DESeq2 Love et al., 2014 N/A
g:Profiler Reimand et al., 2011 N/A
ZEN 2010 software Zeiss N/A
ZEN 2012 software Zeiss N/A
StepOne software Applied Biosystems N/A
FlowJo software v.7.6.5 FlowJo N/A
BD CellQuest Pro software BD Biosciences N/A
GraphPad Prism 7 GraphPad software N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kevin M.
Ryan (k.ryan@beatson.gla.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
KP-4 cells (RIKEN, Cat#: RCB1005) were cultured in IMDM (Thermo Fisher Scientific, Cat#: 21980065) supplemented with 20% FBS
(Thermo Fisher Scientific, Cat#: 10270106) and antibiotics (Thermo Fisher Scientific, Cat#: 15140122) in a humidified atmosphere
with 5% CO2. PA-TU-8902 (DMSZ, Cat#: ACC-179), SUIT2 (JCRB, Cat#: JCRB1094), PA-TU-8988T (DMSZ, Cat#: ACC-162),
hTERT-HPNE (ATCC, Cat#: CRL-4023), IMR90 ER-HRas G12V (a gift from Peter D. Adams, Cancer Research UK Beatson
Institute, UK), and HEK293T (ATCC, Cat#: CRL-3216) cells were maintained in DMEM (Thermo Fisher Scientific, Cat#: 21969035)
supplemented with 10% FBS, 2 mM L-Glutamine (Thermo Fisher Scientific, Cat#: 25030032), and antibiotics. PK-1 (RIKEN,
Cat#: RCB1972) and TY-82 (JCRB, Cat#: JCRB1330) were maintained in RPMI-1640 (Thermo Fisher Scientific, Cat#: 31870074)
supplemented with 10% FBS, 2 mM L-Glutamine, and antibiotics. For starvation experiments, cells were cultured in EBSS
(Sigma-Aldrich, Cat#: E2888). Since amino acid-free and glucose-free IMDM media are not commercially available, we used amino
acid-free and glucose-free DMEM media supplemented with 20% FBS. For amino acid starvation, DMEM low glucose amino acid
free (USBiological, Cat#: D9800-13) was supplemented with Glucose (Thermo Fisher Scientific, Cat#: 15023021) to 25 mM, 20%
dialized FBS (Thermo Fisher Scientific, Cat#: 26400044), 1 mM Sodium pyruvate (Sigma-Aldrich, Cat#: S8636), 3.7 g/L Sodium
bicarbonate (Sigma-Aldrich, Cat#: S5761), and antibiotics. For glucose starvation, DMEM no glucose (Thermo Fisher Scientific,
Cat#: 11966-025) was supplemented with 20% dialized FBS, 1 mM Sodium pyruvate, and antibiotics. DMEM supplemented with
20% dialized FBS, 2 mM L-Glutamine, and antibiotics was used as a control for amino acid and glucose starvation.e4 Molecular Cell 66, 517–532.e1–e9, May 18, 2017
Mice
6-8 week old TRE-shRen/CAG-rtTA3 and TRE-shBRD4/CAG-rtTA3 mice were fed with 625 mg/kg doxycycline-containing food pel-
lets (Harlan Teklad) for 2 weeks. Tissues were harvested and fixed overnight in 10% neutral buffered formalin, followed by paraffin
embedding and sectioning as described previously (Bolden et al., 2014). All experimental procedures were approved by, and
adhered to guidelines of, the Memorial Sloan Kettering Cancer Center institutional animal care and use committee.
METHOD DETAILS
Reagents
Chloroquine (Cat#: C6628), Doxycycline (Cat#: D9891), Antimycin A (Cat#: A8674), Oligomycin (Cat#: O4876), D-(+)-Trehalose dihy-
drate (Cat#: T0167), and 4-Hydroxytamoxifen (Cat#: H7904) were from Sigma-Aldrich. (+)-JQ1 (Cat#: 4499) and I-BET151 (Cat#:
4650) were from TOCRIS. OTX015 (Cat#: 15947) was from Cayman. Compound C (Cat#: 171264) was from EMDMillipore. Rapamy-
cin (Cat#: R-5000) was from LC Laboratories. ARV-825 was from Chemietek (Cat#: CT-ARV825).
Plasmid Transfection
Plasmids were transfected into HEK293T cells using Lipofectamine2000 (Thermo Fisher Scientific, Cat#: 11668027) or GeneJuice
(EMD Millipore, Cat#: 70967). KP-4 cells were transfected with plasmids using Lipofectamine3000 (Thermo Fisher Scientific,
Cat#: L3000015).
siRNA Transfection
Cells were reverse-transfected with 20 nM of siRNAs using Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific, Cat#:
13778150) for 72 hr. siRNAs are listed in Table S1. BRD4 #1-#4 were used to knockdown both short and long isoforms. Since
NUT is a testis-specific gene, NUT siRNAs were used to knockdown BRD4-NUT fusion gene (Schwartz et al., 2011).
Western Blotting
Cells were lysed with cell lysis buffer (20 mM HEPES-KOH pH7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100) containing Halt pro-
tease inhibitor cocktail (Thermo Scientific, Cat#: 78430). Total protein concentration was determined by BCA assay using Copper (II)
sulfate solution (Sigma-Aldrich, Cat#: C2284) and Bicinchoninic Acid solution (Sigma-Aldrich, Cat#: B9643). The cell extracts were
mixed with 6x SDS-PAGE sample buffer (0.3 M Tris-HCl (pH6.8), 0.12 g/ml SDS, 0.1 M Dithiothreitol, 60% Glycerol, 0.6 mg/ml Bro-
mophenol blue) and heated at 99C for 5 min. The same amount of protein (10-30 mg) was loaded and run on SDS-PAGE. The
following antibodies were used. BRD4 E2A7X (long isoform) (Cat#: 13440S, WB 1/1000, IP, ChIP), NUT (Cat#: 3625S, WB
1/1000), G9a (Cat#: 3306S, WB 1/1000), SIRT1 (Cat#: 9475P, WB 1/1000), DBC1 (Cat#: 5857S, WB 1/1000, IP), AMPKa pT172
(Cat#: 2535S, WB 1/1000), AMPKa1/a2 (Cat#: 2793S, WB 1/1000), LC3B (Cat#: 2775S, WB 1/1500), LC3B D11 (Cat#: 3868S, IF
1/200), TFEB (Cat#: 4240S, WB 1/1000), LAMP1 (Cat#: 9091P, WB 1/1000, IF 1/200), CTSD (Cat#: 2284S, WB 1/1000), ASM
(Cat#: 3687S, WB 1/1000), CTSB (Cat#: 31718S, WB 1/1000), ATG5 (Cat#: 12994S, WB 1/1500), p70 S6K pT389 (Cat#: 9234S,
WB 1/1000), p70 S6K (Cat#: 2708S, WB 1/1500), Histone H4K16Ac (Cat#: 13534S, WB 1/1000), Histone H4 (Cat#: 2935P, WB
1/1000), c-Myc (Cat#: 5605S, WB 1/1000), CDK9 (Cat#: 2316T, WB 1/1000), GFP (Cat#: 2956S, WB 1/2000), TFE3 (Cat#:
14779S, WB 1/1000), Normal rabbit IgG (Cat#: 2729S, IP, ChIP), Mouse IgG1 isotype control (Cat#: 5415S, IP), Anti-rabbit IgG
HRP-linked Antibody (Cat#: 7074S, WB 1/5000), and Anti-mouse IgG HRP-linked Antibody (Cat#: #7076S, WB 1/5000) were from
Cell Signaling Technology. BRD4 NT (short and long isoforms) (Cat#: ab128874, WB 1/1000), GAPDH (Cat#: ab9484, WB 1/2000),
b-Actin (Cat#: ab8227, WB 1/2000), G9a (Cat#: ab133482, WB 1/1000, IP, ChIP), H3K9diMe (Cat#: ab1220, ChIP), GAA (Cat#:
ab137068, WB 1/1000), Membrane Integrity WB Antibody Cocktail (Cat#: ab110414 (MS620), WB 1/5000), and Anti-Goat IgG
H&L (HRP) (Cat#: ab6741, WB 1/5000) were from Abcam. BRD4 (long isoform) (Cat#: A301-985A50, ChIP, IHC 1/2000), BRD2
(Cat#: A302-583A, WB 1/5000), BRD3 (Cat#: A302-368A, WB 1/5000), and hMOF (Cat#: A300-992A, WB 1/1000) were from Bethyl
Laboratories. H4K16Ac (Cat#: 07-329, WB 1/2000, ChIP) was from Millipore. H4K16Ac (Cat#: 39167, ChIP) was from Active motif.
LAMP2/CD107b (Cat#: 555803, WB 1/2000) and p62 (Cat#: 610833, WB 1/5000) were from BD. GFP (Cat#: MMS-118P, WB
1/5000) was from Covance. LaminA/C (Cat#: sc-6215, WB 1/2000) and Hsp90b (Cat#: sc-1057, WB 1/2000) were from Santa
Cruz. FLAG (Cat#: F1804, WB 1/2000) was Sigma-Aldrich. V5 (Cat#: 46-0705, WB 1/2000) was from Invitrogen. WIPI2 (Cat#:
MCA5780GA, IF 1/200) was from Bio-Rad. LC3B (Cat#: 0231-100/LC3-5F10, IHC: 1/50) was from NanoTools. Proteins were de-
tected using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Cat#: 32106) or SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Fisher Scientific, Cat#: 34095). Signal intensity was measured using ImageJ64 software (https://
imagej.nih.gov/ij/).
Plasmids, sgRNAs, and shRNAs
cDNA encoding human BRD4 transcript variant long was excised from pRetrox-tight-puro-HA-BRD4 (obtained from MRC
Protein Phosphorylation and Ubiquitylation Unit, Cat#: DU46347) and inserted into pBabe-puro (a gift from Hartmut Land & Jay
Morgenstern & Bob Weinberg, Addgene plasmid # 1764) (Morgenstern and Land, 1990) and pLenti-puro (a gift from Ie-Ming Shih,Molecular Cell 66, 517–532.e1–e9, May 18, 2017 e5
Addgene plasmid # 39481) (Guan et al., 2011) vectors. Human BRD4 transcript variant short was cloned using pRetrox-tight-puro-
HA-BRD4 as a template with BRD4 Short Fw (CGCGATATCACCATGGACTACAAAGACGATGACGACAAGATGTCTGCGGAG
AGCGG) and BRD4 Short Rv (CGCGTCGACTTAGGCAGGACCTGTTTCGGAGTCTTCGCTG) primers. The fragment was digested
with EcoRV and SalI and inserted into pcDNA3 vector (Invitrogen) (EcoRV and XhoI sites). The sequence was confirmed to be iden-
tical to BRD4 transcript variant short (RefSeq: NM_014299.2). mRFP-GFP-LC3 cDNA was excised from pEGFP-C1+mRFP-LC3
(a kind gift from Tamotsu Yoshimori, Osaka University, Japan) (Kimura et al., 2007) and inserted into pBabe-puro vector. pLZRS-
YFP-Parkin was described in (Baudot et al., 2015). pLenti6-MK1-EHMT2 (G9a)-V5 was a gift from Bernard Futscher (Addgene
plasmid # 31113). pTreTight-Htt94Q-CFP was a gift from Nico Dantuma (Addgene plasmid #23966) (Maynard et al., 2009).
pMA2640 was a gift from Mikhail Alexeyev (Addgene plasmid #25434) (Alexeyev et al., 2010). pFlag-CMV2-Brd4 (1-1362) was a
gift from Eric Verdin (Addgene plasmid #22304) (Bisgrove et al., 2007). psPAX2 and pMD2.G were gifts from Didier Trono (Addgene
plasmid #12260 and #12259). pMXs-puro GFP-p62 was a gift from Noboru Mizushima (Addgene plasmid #38277) (Itakura and Miz-
ushima, 2011). pEGFP-N1-TFEB, pEGFP-N1-TFE3 and pEGFP-N1-MITF-A were gifts from Shawn Ferguson (Addgene plasmid
#38119, #38120 and #38132) (Roczniak-Ferguson et al., 2012). GFP-HTT exon1 Q74 cDNA was excised from pEGFP-Q74 (a gift
from David Rubinsztein, Addgene plasmid #40262) (Narain et al., 1999) and inserted into pLVX-TetOne-puro vector (Clontech,
Cat#: 631849). pTRE-tight and pEGFP-N1 vectors were from Clontech (Cat#: 631059 and 6085-1). lentiCRISPR v2 was a gift
from Feng Zhang (Addgene plasmid #52961) (Sanjana et al., 2014).
The following sgRNA sequences were used in the experiments.
Human hMOF/KAT8 #1: CCTTCCCGCGATGGCGGCAC (Wang et al., 2014);
Human hMOF/KAT8 #2: GGCGGCACAGGGAGCTGCTG (Wang et al., 2014);
Human SIRT1: AGAGATGGCTGGAATTGTCC (Wang et al., 2014);
Human AMPKa1/PRKAA1: AAGATCGGCCACTACATTCT (Wang et al., 2014);
Human AMPKa2/PRKAA2: GCTGAGAAGCAGAAGCACGA (Wang et al., 2014);
Human ATG5: AAGAGTAAGTTATTTGACGT (Designed using Optimized CRISPR Design (http://crispr.mit.edu);
Non-targeting control (NTC): GTAGCGAACGTGTCCGGCGT (Wang et al., 2014).
pLKO.1-non-targeting control (NTC) (Sigma-Aldrich, Cat#: SHC002) and pLKO.1-shG9a #1 and #2 (Dharmacon, Cat#:
TRCN0000115670 (#1) and TRCN0000115668 (#2)) were purchased from Sigma-Aldrich and Dharmacon, respectively. pTRIPZ-
non-targeting control (NTC) (Cat#: RHS4743) and shBRD4 (Cat#: V3THS326487) were purchased from Dharmacon.
Lentivirus and Retrovirus Production and Infection
Lentiviral plasmids were transfected into HEK293T cells together with packaging and envelope plasmids (psPAX2 and pMD2.G) us-
ing Lipofectamine2000 (Thermo Fisher Scientific, Cat#: 11668027) or Genejuice (EMD Millipore, Cat# 70967). At 2 days after trans-
fection, the medium was passed through a 0.45 mm pore filter and mixed with Polybrene (Sigma-Aldrich, Cat#: H9268). The medium
containing lentiviruses was transferred to the recipient cells. HEK293T cells were further cultured in fresh medium for 24 hr. After
6 hr of infection, medium was changed. Next day, infection was repeated as above. After lentivirus infection, cells were selected
with 1 mg/ml of Puromycin (Sigma-Aldrich, Cat#: P9620) or 5 mg/ml of Blasticidin (Thermo Fisher Scientific, Cat# R21001) for
5-10 days. For retrovirus production, retroviral plasmids were transfected into Phoenix-AMPHO cells (ATCC, Cat#: CRL-3213) using
Lipofectamine2000 or Genejuice. Retrovirus infection was carried out as described above.
Immunofluorescence and Confocal Imaging
Cells seeded on coverslips (VWR 16mm, Thickness No.1, Cat# 631-0152) were fixed with 4% PFA/PBS (Electron microscopy sci-
ence, Cat#: 1570) at RT for 15 min followed by permeabilization with 0.1% Triton X-100/PBS. For LC3 and WIPI2 staining, cells
were fixed and permeabilized in 100% ice-cold methanol at 20C for 15min. After incubation in blocking solution (3% BSA/PBS)
at room temperature for 1hr, cells were incubated with primary antibody at 4C overnight. Cells were washed in PBS three times
and stained with 2 mg/ml Hoechst33342 (Thermo Fisher Scientific, Cat#: H3570) for 15min at room temperature, followed by wash
in PBS three times. Cells were then incubated with Anti-rabbit IgG-Alexa 488 (Thermo Fisher Scientific, Cat#: A11008, 1/1000) or
Anti-mouse IgG-Alexa 568 (Thermo Fisher Scientific, Cat#: A11031, 1/1000) for 1hr at room temperature. After cells were washed
with PBS four times, the coverslips were mounted onto glass slides using Fluorescent Mounting Medium (DAKO, Cat#: S3023).
To visualize acidic lysosome compartments, cells were stained with LysoTracker Red DND-99 (Thermo Fisher Scientific, Cat#
L7528, 100 nM, 2 hr). To measure lysosomal Cathepsin B activity, cells were incubated with Magic Red CathepsinB (ImmunoChem-
istry Technologies, Cat#: 938) for 1 hr according to the manufacturer’s instructions. After incubation with LysoTracker Red or Magic
Red CathepsinB, cells were fixed in 4%PFA/PBS for 15 min at room temperature. Cells were then washed in PBS five times followed
by staining with 2 mg/ml Hoechst33342 for 15 min at room temperature. Cells were washed with PBS four times and the coverslips
were mounted onto glass slides using Fluorescent Mounting Medium. All confocal images were acquired and processed using
a Zeiss 710 confocal microscope (Zeiss) and Zen2010 software (Zeiss). The number of LC3 and WIPI2 puncta were counted usinge6 Molecular Cell 66, 517–532.e1–e9, May 18, 2017
CellProfiler software (http://cellprofiler.org) and normalized to the number of nuclei. The area of LAMP-1-, LysoTracker Red-, and
Magic Red CathepsinB-positive compartments was measured using ImageJ64 software (https://imagej.nih.gov/ij/) and normalized
to the number of nuclei.
Immunohistochemistry
Transgenic mice harboring inducible Renilla luciferase and BRD4 shRNAs whose expression is under the control of TRE promoter
were generated as described previously using the same shRNA sequences (Bolden et al., 2014). Briefly ESCs containing a homing
cassette at the Col1a1 locus were targeted with TRE-driven single-copy shRNAs and mice were generated by blastocytst injections.
Resulting F1micewere crossed to the CAG-rtTA3 strain (Premsrirut et al., 2011). Doxycycline was administered to 6-8 week old TRE-
shRen/CAG-rtTA3 or TRE-shBRD4/CAG-rtTA3 mice via 625 mg/kg doxycycline-containing food pellets (Harlan Teklad) for 2 weeks.
JQ1 preparation and administration were performed as described previously (Bolden et al., 2014). JQ1 powder was dissolved in
DMSO to generate a concentrated 50 mg/mL stock solution. For administration to animals, a working solution was generated by
diluting 1 part of the concentrated JQ1stock drop-wise into 9 parts 10% 2-(Hydroxypropyl)-b-cyclodextrin (Sigma-Aldrich,
Cat#: C0926). C57BL/6 mice received once daily intraperitoneal injections of 100 mg/kg JQ1 for 2 weeks. Tissues were harvested
and fixed overnight in 10%neutral buffered formalin, followed by paraffin embedding and sectioning as described previously (Bolden
et al., 2014). All experimental procedures were approved by, and adhered to guidelines of, the Memorial Sloan Kettering Cancer
Center institutional animal care and use committee.
Paraffin embedded sections were placed in Xylene for 5 min, 100% Ethanol for 1 min twice, 70% Ethanol for 1 min, and deionized
water for 5 min. Antigen retrieval was performed in PTModule using Sodium citrate retrieval buffer pH 6 (Thermo Scientific, Cat#: TA-
250-PM1X) at 98C for 25 min followed by wash with Tris buffered saline and tween 20 (TBST) (Thermo Scientific, Cat#: TA-999-TT).
The sections were then blocked for endogenous peroxidase using Peroxidase-blocking solution (Dako, Cat#: S2023) for 5 min fol-
lowed by wash with TBST. The sections were incubated with LC3B (NanoTools, Cat#: 0231-100/LC3-5F10, 1/50) or BRD4 (Bethyl
Laboratories, Cat#: A301-985A50, 1/2000) antibody diluted in Antibody diluent (Dako, Cat#: S2022) for 35 min. After wash with
TBST twice, the sections were incubated with EnVision+ HRP, Mouse or Rabbit (Dako, Cat#: K4001 and K4003) for 30 min followed
by wash with TBST twice. The sections were incubated with 3,30-Diaminobenzidine tetrahydrochloride (DAB) (Dako, Cat#: K3468) for
10 min, washed with deionized water for 1 min, stained with Haematoxylin Z (CellPath, Cat#: RBA-4201-00A) for 7 min, washed with
deionized water for 1min, differentiated in 1% Acid alcohol, washed with deionized water for 30 s, incubated in Scott’s tap water
substitute for 1 min, and washed with deionized water for 1 min. The sections were dehydrated, cleaned, and mounted with DPX.
Images were acquired using a Zeiss Axio Scope.A1 microscope (Zeiss) and ZEN 2012 software (Zeiss).
To measure LC3 lipidation levels in BRD4 knockdown and JQ1-treated mice, proteins were extracted from formalin-fixed paraffin-
embedded (FFPE) tissues using Qproteome FFPE Tissue Kit (QIAGEN, Cat#: 37623). Total protein concentration was determined by
Bradford assay (Bio-Rad, Cat#: 500-0201). The cell extracts were mixed with 6x SDS-PAGE sample buffer and heated at 99C for
5 min. The same amount of protein (20-30 mg) was loaded and run on SDS-PAGE. To confirm BRD4 knockdown, total RNA was iso-
lated from FFPE tissues using RNeasy FFPE kit (QIAGEN, Cat#: 73504) followed by RT-qPCR analysis described below.
RNA Sequencing
KP-4 cells were transfected with Control #1, BRD4 #1, or BRD4 #2 siRNA for 72 hr. At 72 hr after transfection, total RNA was isolated
and purified using RNeasymini kit (QIAGEN, Cat#: 74104). Quality of the purified RNAwas assessed using an Agilent RNA 6000Nano
kit and 2100 Bioanalyzer. Libraries for cluster generation and DNA sequencing were prepared following an adapted method from
(Fisher et al., 2011) using TruSeq RNA Sample Prep Kit v2 (Illumina, Cat#: RS-122-2001). Quality and quantity of the DNA libraries
were assessed on an Agilent 2100 Bioanalyser and Qubit (Thermo Fisher Scientific), respectively. The libraries were run on the Illu-
mina Next Seq 500 using the High Output 75 cycles kit (2x36 cycles, paired end reads, single index). The results were then analyzed
as follows. Quality checks on the rawRNA-Seq data fileswere conducted using fastqc (https://www.bioinformatics.babraham.ac.uk/
projects/fastqc/) and fastq_screen (http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/). RNA-Seq reads were
aligned to the GRCh37 (Church et al., 2011) version of the human genome using tophat2 version 2.0.10 (Kim et al., 2013) with Bowtie
version 2.1.0 (Langmead and Salzberg, 2012). Expression levels were determined and statistically analyzed by a combination of
HTSeq version 0.5.4p3 (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html), the R 3.1.1 environment, utilizing
packages from the Bioconductor data analysis suite and differential gene expression analysis based on a generalized linear model
using the DESeq2 (Love et al., 2014). Enrichment analysis for Gene Ontology terms within this gene set was performed using
g:Profiler (Reimand et al., 2011).
RNA Isolation, Reverse Transcription, and Quantitative PCR (RT-qPCR)
The total RNA was isolated and purified using the RNeasy mini kit (QIAGEN, Cat#: 74104). 1 mg of total RNA was reverse-transcribed
using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems, Cat# 4387406) at 37C for 1 hr. 1 mL of cDNA from 20 mL reaction
volume was used for qPCR. qPCR was run on a StepOnePlus (Applied Biosystems) using Fast SYBR Green Master Mix (Applied
Aiosystems, Cat#: 4385617). mRNA levels were determined by the relative standard curve method, normalized to 18S, GAPDH,
or HPRT levels, and presented as relative mRNA levels. qPCR analyses were done in triplicate. Experiments were repeated at least
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Co-immunoprecipitation
Cells were lysed in cell lysis buffer (20 mM HEPES-KOH pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100) containing Halt pro-
tease inhibitor cocktail (Thermo Fisher Scientific, Cat#: 78430). Lysates were incubated with 1 mg of antibody or control rabbit or
mouse IgG (Cell Signaling Technology, Cat#: 2729S and 5415S) at 4C overnight followed by incubation with 50 mL of Dynabeads
Protein G (Thermo Fisher Scientific, Cat# 10004D) for 3 hr. After washing 3 times with cell lysis buffer containing 0.05% NP-40, im-
munoprecipitates were resuspended in 1x SDS-PAGE sample buffer and resolved by SDS-PAGE followed by western blot analysis.
Chromatin Immunoprecipitation
Approximately 7x106 cells were fixed with 1% Formaldehyde (Sigma-Aldrich, Cat#: F8775) at room temperature for 10 min and
quenched by adding Glycine at a final concentration of 125 mM. Cells were then harvested and lysed in 500 mL of ChIP lysis Buffer
(50 mM Tris-HCl pH8.0, 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.5% SDS, 0.5% NP-40, 1 mM Sodium butylate) containing
Halt protease inhibitor cocktail. The lysates were subjected to sonication to shear DNA to the length of approximately between 150
and 900 bp using a Bioruptor (Diagenode). 300 mL of the lysate were then diluted in 1.2 mL of ChIP dilution buffer (50 mM Tris-HCl
pH8.0, 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP-40, 1 mM Sodium butylate) containing Halt protease inhibitor cock-
tail, and incubated with control IgG (Cell Signaling Technology, Cat#: 2729S) or primary antibody together with 50 mL of Dynabeads
protein G (Thermo Fisher Scientific, Cat# 10004D) at 4C overnight. The beads were washed sequentially with the following buffers:
ChIP dilution buffer, high salt wash buffer twice (50mMTris-HCl pH8.0, 5mMEDTA, 600mMNaCl, 0.5% Triton X-100, 0.5%NP-40),
LiCl wash buffer twice (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), ChIP dilution
buffer, and wash buffer 4 (10 mM Tris-HCl, pH 8.0, 0.1% NP-40). The immunocomplexes were eluted with 75 mL of elution buffer
(1% SDS, 0.1 M NaHCO3) twice at 65
C for 30 min. After elution, the cross-link was reversed by adding NaCl to a final concentration
of 200 mM and incubated together with Proteinase K (Thermo Fisher Scientific, Cat#: EO0491) for 6 hr at 65C. 3M Sodium acetate
solution pH5.2 (Thermo Fisher Scientific, Cat#: R1181) was added to the eluate to lower pH. DNA fragments were purified with the
QIAquick PCR purification kit (QIAGEN, Cat#: 28104). The purified DNA was analyzed on a StepOnePlus using Fast SYBR Green
Master Mix. The results are presented as percentage of input. qPCR analyses were done in triplicate. Experiments were repeated
at least twice. Primers are listed in Table S2.
RNAi in Drosophila S2R+ cells
Culture of Drosophila S2R+ cells, generation of S2R+ cells stably expressing GFP-LC3, delivery of control luciferase and Fs(1)h
dsRNAs into GFP-LC3 expressing S2R+ cells, and subsequent confocal microscopic analysis were described previously (Wilkinson
et al., 2011).
b-Hexosaminidase Assay
Lysosomal b-Hexosaminidase activity was measured as described in (Chauhan et al., 2013). An equal number of KP-4 cells
(3x105 cells) were lysed in 50 mL of 0.1% Triton X-100 containing Halt protease inhibitor cocktail. 20 mL of the cell extracts were
then incubated with 1 mM 4-Nitrophenyl N-acetyl-b-D-glucosaminide (p-NAG) (Sigma-Aldrich, Cat#: N9376) at 37C for 1.5 hr.
The reactionwas stopped by adding 0.1MCarbonate/bicarbonate (Sigma-Aldrich, Cat#: C3041). The amount of the reaction product
was measured by reading the absorbance at 405nm.
Aggrephagy
Effects of BRD4 knockdown and overexpression on aggrephagy were examined as described in (Bauer et al., 2010). KP-4 cells
harboring rtTA and Tre-tight-HTT Q94-CFP were treated with 1 mg/ml of Doxycycline (DOX) for 10 hr. Cells were then washed
with PBS three times and cultured in fresh medium. At 48 hr after removal of DOX, cells were lysed in cell lysis buffer and separated
into Triton X-100 soluble and insoluble fractions. Triton X-100 insoluble fraction waswashedwith lysis buffer three times. Triton X-100
soluble fraction was mixed with 6x SDS-PAGE sample buffer and Triton X-100 insoluble fraction was resuspended in 1x SDS-PAGE
sample buffer followed by SDS-PAGE and western blot. To determine the effect of mutant HTT on cell number, HTT exon1 Q74 was
overexpressed in cells as described in (Williams et al., 2008). KP-4 cells infected with pLVX-TetOne-GFP-HTT Q74 and control
parental cells were treated with 100 ng/ml DOX for 60 hr. Cell number of mutant HTT expressing cells was normalized to that of
parental cells and presented as percentage of reduction in cell number upon mutant HTT induction. Cell number of KP-4 pLVX-
GFP-HTT Q74 and parental control cells was comparable in the absence of DOX (data is shown in Figure S6K first lane).
Mitophagy
Effects of BRD4 knockdown and overexpression onmitophagywere examined as described in (Baudot et al., 2015). KP-4 cells stably
expressing YFP-parkin were treated with 1 mM of Antimycin A and Oligomycin for 8 hr. Degradation of mitochondrial proteins was
monitored as a readout for mitophagy.
Xenophagy
KP-4 cells were plated in triplicates at 8x104 cells in 6-well plates and reverse-transfected with 20 nM of siRNAs using Lipofectamine
RNAiMAX. Infection with Salmonella enterica serovar Typhimurium (strain 12023) was performed 48 hr after siRNA transfection ase8 Molecular Cell 66, 517–532.e1–e9, May 18, 2017
described previously (McEwan et al., 2015b). Therefore, an overnight (stationary) culture of Salmonella was diluted 1:33 and incu-
bated for 3 hr at 37C prior to infection. The culture was diluted 1:250 to infect cells and Salmonella were allowed to invade cells
for 15 min. Afterward, cells were washed with EBSS and incubated for 1 hr in media containing 100 mg/ml gentamycin. Media
was replaced with 20 mg/ml gentamycin thereafter. To enumerate intracellular Salmonella, cells were lysed 2, 6 or 8 hr post infection
in PBS with 0.1% Triton X-100. Lysates were serial diluted and plated in duplicates on Agar plates.
Cell Proliferation and Cell Death Assays
For EdU staining, KP-4 cells were treated with 10 mM EdU for 2 hr before fixation. Cells were then subjected to EdU staining using
Click-iT EdU FlowCytometry Assay Kit (Thermo Fisher Scientific, Cat#: C10633). Sampleswere then stainedwith FxCycle PI/RNAase
staining solution (Thermo Fisher Scientific, Cat#: F10797) and analyzed on a FACSCalibur (BD Biosciences). Percentage of EdU pos-
itive cells was calculated using FlowJo software. Cell number was determined by using a CASY cell counter (Roche Innovatis) or by
Trypan blue exclusion test using Trypan blue solution (Sigma-Aldrich, Cat#: T8154). To determine the sub G1 population, cells were
fixed with 10% methanol followed by staining with 50 mg/ml Propidium iodide (Sigma-Aldrich, Cat#: P4170) containing 50 mg/ml
RNase A (QIAGEN, Cat#: 19101). Cells were then analyzed on a FACSCalibur using BD CellQuest Pro software (BD Biosciences).
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of Western Blotting
Quantification of western blotting was performed using ImageJ64 software (https://imagej.nih.gov/ij/) using Gel analyzer script.
Signal intensity of the protein of interest was normalized to that of loading control (GAPDH, Hsp90, or b-actin).
Quantification of Microscopic Images
The number of LC3 andWIPI2 puncta were counted using CellProfiler software (http://cellprofiler.org) and normalized to the number
of nuclei. The area of LAMP-1-, LysoTracker Red-, and Magic Red CathepsinB-positive compartments was measured using
ImageJ64 software (https://imagej.nih.gov/ij/) and normalized to the number of nuclei.
Quantification of the qPCR Results
Target mRNA levels were determined by relative standard curve method, normalized to 18S, GAPDH, or HPRT levels, and presented
as relative mRNA levels compared to control. StepOne software (Applied Biosystems) was used to analyze the data.
Statistical Analyses
All studies were performed on at least three independent occasions. Results are shown as mean ± SD unless mentioned otherwise.
Statistical significance was determined by two-tailed unpaired Student’s t test for two group comparison and one-way ANOVA with
Tukey or Dunnett for multiple group comparison using GraphPad Prism 7 (GraphPad software). P values < 0.05 were considered sig-
nificant. Significance in all figures is indicated as follows: * p < 0.01, ** p < 0.05, N.S.: no significance.
DATA AND SOFTWARE AVAILABILITY
The raw and processed data of the RNA-Seq have been deposited in Gene Expression Omnibus under GEO: GSE90444. Full scans
of western blot data and original microscopy images have been deposited in Mendeley Data (http://dx.doi.org/10.17632/
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